MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial Condition

30

MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Results of Operations and Financial Condition

On July 13, 2017, MiMedx Group, Inc. (the “Company”) issued a press release providing certain financial results for the second quarter of 2017, as well as certain other matters.A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided to Item 2.02 of this Form 8-K is to be considered “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits

Exhibit No.

Description

99.1

MiMedx Group, Inc. Press Release, dated July 13, 2017


MIMEDX GROUP, INC. Exhibit
EX-99.1 2 exhibit99171717.htm EXHIBIT 99.1 Exhibit Exhibit 99.1MiMedx Announces that its Second Quarter Revenue Exceeds the Guidance Range Q2 2017 Revenue of $76.4 Million is 33% Increase Over Q2 2016MARIETTA,…
To view the full exhibit click here

About MIMEDX GROUP, INC. (NASDAQ:MDXG)

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.

An ad to help with our costs